Friday, 29 November 2024 11:36

HRT patches decision needs reconsideration - RWNZ

Written by  Jessica Marshall
RWNZ president Sandra Matthews. RWNZ president Sandra Matthews.

Rural Women New Zealand (RWNZ) says Pharmac needs to reconsider its decision to fund only one brand of hormone replacement therapy (HRT) patches used by women going through perimenopause and menopause.

Earlier this week, Pharmac announced that Estradiol TDP Mylan would be the main funded brand of oestradiol patches from 1 July 2025 and would be the only funded brand available from 1 December 2025.

According to Pharmac, in the past three years, demand for oestradiol has tripled and is expected to continue rising.

The Mylan patches have been provisionally approved by Medsafe and Pharmac says it anticipates full approval by Medsafe before 1 July 2025.

The decision has been met with concern and outrage, with a petition being launched asking the government to step in and reverse the decision.

RWNZ national president Sandra Matthews says that while her organisation is pleased to see a more secure supply chain for oestradiol patches and gel after recent global shortages, the decision to limit the funded brands will remove “freedom of choice for women to make the right choice for their bodies”.

“This is causing concern for many women around New Zealand, many of whom have tried several different types of HRT patches before finding the right one,” Matthews says.

“Managing menopause is a major part of a woman’s life and this decision is affecting many women’s health, wellbeing and welfare during and already incredibly challenging period of their lives,” she says.

Matthews claims the decision is also inequitable because women who prefer other brands will need to fund them themselves or face using a brand that doesn’t work for them or could cause adverse effects.

“We call on Pharmac to do the right thing by women and reconsider its decision to de-list existing available brands,” she concludes.

Meanwhile, Pharmac chief executive Sarah Fitt says she understands people are concerned by the decision, but adds that it was Pharmac’s only option given the continuing supply issue.

“Pharmac has been managing ongoing supply shortages of the current oestradiol patches for several years, and we know that’s been very difficult for people,” Fitt says.

“Based on the information from the current supplier, Sandoz, it is unable to fully meet our supply needs with Estradot due to the continually increasing demand The company we will contract with, Viatris, has provided an assurance that it is able to meet current and future demand – making it the only viable option,” she says.

Fitt notes that the new brand may not be suitable for all women and so is working to ensure there is an alternative option available if needed.

“We’re still working out the details and we’ll share that information once it’s confirmed.”

More like this

Featured

$2b boost in NZ exports to EU

New Zealand’s trade with the European Union has jumped $2 billion since a free trade deal entered into force in May last year.

US tariffs hit European ag machinery markets

The climate of uncertainty and market fragmentation that currently characterises the global economy suggests that many of the European agricultural machinery manufacturers will be looking for new markets.

Tributes paid to Jim Bolger

Dignitaries from  all walks of life – the governor general,  politicians past and present, Maoridom- including the Maori Queen, church leaders, the primary sector and family and  friends packed Our Lady of Kapiti’s Catholic church in Paraparaumu on Thursday October 23 to pay tribute to former prime Minister, Jim Bolger who died last week.

National

Machinery & Products

» Latest Print Issues Online

The Hound

Red faced

OPINION: The Greens have taken the high moral ground on the Palestine issue and been leading political agitators in related…

Cold comfort

One of the most galling aspects of the tariffs whacked on our farm exports to the US is the fact…

» Connect with Rural News

» eNewsletter

Subscribe to our weekly newsletter